메뉴 건너뛰기




Volumn 45, Issue , 2015, Pages 69-75

The futility study-Progress over the last decade

Author keywords

Futility design; Non superiority design; Phase II trials; Screening program

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); EVALUATION STUDY; HUMAN; METHODOLOGY; NEUROLOGIC DISEASE; NEUROLOGY; NULL HYPOTHESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SCREENING; STUDY DESIGN; NERVOUS SYSTEM DISEASES; PROCEDURES; STATISTICAL MODEL;

EID: 84955699842     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2015.06.013     Document Type: Article
Times cited : (15)

References (45)
  • 1
    • 50549174560 scopus 로고
    • The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent
    • Gehan E.A. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J. Chronic Dis. 1961, 13:346-353.
    • (1961) J. Chronic Dis. , vol.13 , pp. 346-353
    • Gehan, E.A.1
  • 2
    • 0018596257 scopus 로고
    • Predictive probability early termination plans for phase II clinical trials
    • Herson J. Predictive probability early termination plans for phase II clinical trials. Biometrics 1979, 35:775-783.
    • (1979) Biometrics , vol.35 , pp. 775-783
    • Herson, J.1
  • 3
    • 0020108590 scopus 로고
    • One-sample multiple testing procedure for phase II clinical trials
    • Fleming T.R. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982, 38:143-151.
    • (1982) Biometrics , vol.38 , pp. 143-151
    • Fleming, T.R.1
  • 4
    • 0024536437 scopus 로고
    • Optimal two-stage designs for phase II clinical trials
    • Simon R. Optimal two-stage designs for phase II clinical trials. Control. Clin. Trials 1989, 10:1-10.
    • (1989) Control. Clin. Trials , vol.10 , pp. 1-10
    • Simon, R.1
  • 6
    • 0037461309 scopus 로고    scopus 로고
    • Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment
    • Ravina B.M., Fagan S., Hart R.G., Murphy D., Marler J.R. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2003, 60:1234-1240.
    • (2003) Neurology , vol.60 , pp. 1234-1240
    • Ravina, B.M.1    Fagan, S.2    Hart, R.G.3    Murphy, D.4    Marler, J.R.5
  • 7
    • 34147164484 scopus 로고    scopus 로고
    • Neuroprotection in Parkinson's disease: an elusive goal
    • Biglan K.M., Ravina B. Neuroprotection in Parkinson's disease: an elusive goal. Semin. Neurol. 2007, 2:106-112.
    • (2007) Semin. Neurol. , vol.2 , pp. 106-112
    • Biglan, K.M.1    Ravina, B.2
  • 8
    • 53449089266 scopus 로고    scopus 로고
    • Neuroprotection in Parkinson's disease: myth or reality?
    • Voss T., Ravina B. Neuroprotection in Parkinson's disease: myth or reality?. Curr. Neurol. Neurosci. Rep. 2008, 8(4):304-309.
    • (2008) Curr. Neurol. Neurosci. Rep. , vol.8 , Issue.4 , pp. 304-309
    • Voss, T.1    Ravina, B.2
  • 9
    • 67651160657 scopus 로고    scopus 로고
    • Neuroprotection trials in Parkinson's disease: systematic review
    • Hart R.G., Pearce L.A., Ravina B.M., Yaltho T.C., Marler J.R. Neuroprotection trials in Parkinson's disease: systematic review. Mov. Disord. 2009, 24(5):647-654.
    • (2009) Mov. Disord. , vol.24 , Issue.5 , pp. 647-654
    • Hart, R.G.1    Pearce, L.A.2    Ravina, B.M.3    Yaltho, T.C.4    Marler, J.R.5
  • 10
    • 0028783948 scopus 로고
    • Tissue plasminogen activator for acute ischemic stroke
    • The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 1995, 333:1581-1588.
    • (1995) N. Engl. J. Med. , vol.333 , pp. 1581-1588
  • 11
    • 80052809265 scopus 로고    scopus 로고
    • Neuroprotective effects of creatine
    • Beal M.F. Neuroprotective effects of creatine. Amino Acids 2011, 40(5):1305-1313.
    • (2011) Amino Acids , vol.40 , Issue.5 , pp. 1305-1313
    • Beal, M.F.1
  • 12
    • 0022787429 scopus 로고
    • Calibrated phase II clinical trials in oncology
    • Herson J., Carter S.K. Calibrated phase II clinical trials in oncology. Stat. Med. 1986, 5:441-447.
    • (1986) Stat. Med. , vol.5 , pp. 441-447
    • Herson, J.1    Carter, S.K.2
  • 13
    • 19944433460 scopus 로고    scopus 로고
    • A responsive outcome for Parkinson's disease neuroprotection futility studies
    • Elm J.J., Goetz C.G., Ravina B., Shannon K., Wooten G.F., Tanner C.M., for the NET-PD Investigators, et al. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann. Neurol. 2005, 57(2):197-203.
    • (2005) Ann. Neurol. , vol.57 , Issue.2 , pp. 197-203
    • Elm, J.J.1    Goetz, C.G.2    Ravina, B.3    Shannon, K.4    Wooten, G.F.5    Tanner, C.M.6
  • 14
    • 33645864949 scopus 로고    scopus 로고
    • Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs
    • Tilley B.C., Palesch Y.Y., Kieburtz K., Ravina B., Huang P., Elm J.J., for the NET-PD Investigators, et al. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology 2006, 66(5):628-633.
    • (2006) Neurology , vol.66 , Issue.5 , pp. 628-633
    • Tilley, B.C.1    Palesch, Y.Y.2    Kieburtz, K.3    Ravina, B.4    Huang, P.5    Elm, J.J.6
  • 15
    • 33645894705 scopus 로고    scopus 로고
    • A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease
    • NINDS NET-PD Investigators A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006, 66(5):664-671.
    • (2006) Neurology , vol.66 , Issue.5 , pp. 664-671
  • 16
    • 44649153832 scopus 로고    scopus 로고
    • A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results
    • NINDS NET-PD Investigators A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin. Neuropharmacol. 2008, 31(3):141-150.
    • (2008) Clin. Neuropharmacol. , vol.31 , Issue.3 , pp. 141-150
  • 17
    • 27644481285 scopus 로고    scopus 로고
    • Applying a phase II futility study design to therapeutic stroke trials
    • Palesch Y.Y., Tilley B.C., Sackett D.L., Johnston K.C., Woolson R. Applying a phase II futility study design to therapeutic stroke trials. Stroke 2005, 36(11):2410-2414.
    • (2005) Stroke , vol.36 , Issue.11 , pp. 2410-2414
    • Palesch, Y.Y.1    Tilley, B.C.2    Sackett, D.L.3    Johnston, K.C.4    Woolson, R.5
  • 19
    • 33846641246 scopus 로고    scopus 로고
    • Screening potential therapies: lessons learned from new paradigms used in Parkinson disease
    • Tilley B.C., Galpern W.R. Screening potential therapies: lessons learned from new paradigms used in Parkinson disease. Stroke 2007, 38(2 Suppl.):800-803.
    • (2007) Stroke , vol.38 , Issue.2 , pp. 800-803
    • Tilley, B.C.1    Galpern, W.R.2
  • 24
    • 78649369122 scopus 로고    scopus 로고
    • A futility study of minocycline in Huntington's disease
    • The Huntington Study Group DOMINO Investigators A futility study of minocycline in Huntington's disease. Mov. Disord. 2010, 25(13):2219-2224.
    • (2010) Mov. Disord. , vol.25 , Issue.13 , pp. 2219-2224
  • 25
    • 79957621566 scopus 로고    scopus 로고
    • Milestones in movement disorders clinical trials: advances and landmark studies
    • Olanow C.W., Wunderle K.B., Kieburtz K. Milestones in movement disorders clinical trials: advances and landmark studies. Mov. Disord. 2011, 26(6):1003-1014.
    • (2011) Mov. Disord. , vol.26 , Issue.6 , pp. 1003-1014
    • Olanow, C.W.1    Wunderle, K.B.2    Kieburtz, K.3
  • 26
    • 84980052961 scopus 로고    scopus 로고
    • Advances in designs for Alzheimer's disease clinical trials
    • Cummings J., Gould H., Zhong K. Advances in designs for Alzheimer's disease clinical trials. Am. J. Neurodegener. Dis. 2012, 1(3):205-216.
    • (2012) Am. J. Neurodegener. Dis. , vol.1 , Issue.3 , pp. 205-216
    • Cummings, J.1    Gould, H.2    Zhong, K.3
  • 27
    • 27644532415 scopus 로고    scopus 로고
    • The utility of futility
    • Levin B. The utility of futility. Stroke 2005, 36:2331-2332.
    • (2005) Stroke , vol.36 , pp. 2331-2332
    • Levin, B.1
  • 28
    • 33744981624 scopus 로고    scopus 로고
    • Issues in neuroprotection clinical trials in Parkinson's disease
    • Kieburtz K. Issues in neuroprotection clinical trials in Parkinson's disease. Neurology 2006, 66(10 Suppl. 4):S50-S57.
    • (2006) Neurology , vol.66 , Issue.10 , pp. S50-S57
    • Kieburtz, K.1
  • 29
    • 33645864950 scopus 로고    scopus 로고
    • Futility studies: spending a little to save a lot
    • Schwid S.R., Cutter G.R. Futility studies: spending a little to save a lot. Neurology 2006, 66(5):626-627.
    • (2006) Neurology , vol.66 , Issue.5 , pp. 626-627
    • Schwid, S.R.1    Cutter, G.R.2
  • 31
    • 34447301510 scopus 로고    scopus 로고
    • Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?
    • Hung A.Y., Schwarzschild M.A. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility?. Curr. Opin. Neurol. 2007, 20(4):477-483.
    • (2007) Curr. Opin. Neurol. , vol.20 , Issue.4 , pp. 477-483
    • Hung, A.Y.1    Schwarzschild, M.A.2
  • 32
    • 84867693278 scopus 로고    scopus 로고
    • Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1
    • Elm J.J., for the NINDS NET-PD Investigators Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Mov. Disord. 2012, 27(12):1513-1521.
    • (2012) Mov. Disord. , vol.27 , Issue.12 , pp. 1513-1521
    • Elm, J.J.1
  • 33
    • 84885177997 scopus 로고    scopus 로고
    • High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods
    • Yeatts S.D., Palesch Y.Y., Moy C.S., Selim M. High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods. Neurocrit. Care 2013, 19(2):257-266.
    • (2013) Neurocrit. Care , vol.19 , Issue.2 , pp. 257-266
    • Yeatts, S.D.1    Palesch, Y.Y.2    Moy, C.S.3    Selim, M.4
  • 34
    • 84882375832 scopus 로고    scopus 로고
    • High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial
    • Lewis R.A., McDermott M.P., Herrmann D.N., Hoke A., Clawson L.L., Siskind C., et al. High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial. JAMA Neurol. 2013, 70(8):981-987.
    • (2013) JAMA Neurol. , vol.70 , Issue.8 , pp. 981-987
    • Lewis, R.A.1    McDermott, M.P.2    Herrmann, D.N.3    Hoke, A.4    Clawson, L.L.5    Siskind, C.6
  • 35
    • 84880282982 scopus 로고    scopus 로고
    • Study in Parkinson disease of exercise (SPARX): translating high-intensity exercise from animals to humans
    • Moore C.G., Schenkman M., Kohrt W.M., Delitto A., Hall D.A., Corcos D. Study in Parkinson disease of exercise (SPARX): translating high-intensity exercise from animals to humans. Contemp. Clin. Trials 2013, 36(1):90-98.
    • (2013) Contemp. Clin. Trials , vol.36 , Issue.1 , pp. 90-98
    • Moore, C.G.1    Schenkman, M.2    Kohrt, W.M.3    Delitto, A.4    Hall, D.A.5    Corcos, D.6
  • 36
    • 33645852575 scopus 로고    scopus 로고
    • A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS
    • Levy G., Kaufmann P., Buchsbaum R., Montes J., Barsdorf A., Arbing R., et al. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 2006, 66:660-663.
    • (2006) Neurology , vol.66 , pp. 660-663
    • Levy, G.1    Kaufmann, P.2    Buchsbaum, R.3    Montes, J.4    Barsdorf, A.5    Arbing, R.6
  • 37
    • 70249116820 scopus 로고    scopus 로고
    • Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III
    • Kaufmann P., Thompson J.L.P., Levy G., Buchsbaum R., Shefner J., Krivickas L.S., for the QALS Study Group, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann. Neurol. 2009, 66:235-244.
    • (2009) Ann. Neurol. , vol.66 , pp. 235-244
    • Kaufmann, P.1    Thompson, J.L.P.2    Levy, G.3    Buchsbaum, R.4    Shefner, J.5    Krivickas, L.S.6
  • 38
    • 84870889573 scopus 로고    scopus 로고
    • Selection and futility designs. Chapter 8
    • Cambridge University Press, Cambridge, B. Ravina, J. Cummings, M.P. McDermott, M. Poole (Eds.)
    • Levin B. Selection and futility designs. Chapter 8. Clinical Trials in Neurology 2012, Cambridge University Press, Cambridge. B. Ravina, J. Cummings, M.P. McDermott, M. Poole (Eds.).
    • (2012) Clinical Trials in Neurology
    • Levin, B.1
  • 39
    • 84880310048 scopus 로고    scopus 로고
    • Novel methodologic approaches to phase I, II, and III trials
    • Yeatts S.D. Novel methodologic approaches to phase I, II, and III trials. Stroke 2013, 44(6 Suppl. 1):S116-S118.
    • (2013) Stroke , vol.44 , Issue.6 , pp. S116-S118
    • Yeatts, S.D.1
  • 40
    • 84889859929 scopus 로고    scopus 로고
    • Clinician-trialist rounds: 18. Should young (and old!) clinician-trialists perform single-arm Phase II futility trials?
    • Sackett D.L. Clinician-trialist rounds: 18. Should young (and old!) clinician-trialists perform single-arm Phase II futility trials?. Clin. Trials 2013, 10(6):987-989.
    • (2013) Clin. Trials , vol.10 , Issue.6 , pp. 987-989
    • Sackett, D.L.1
  • 42
    • 84893488628 scopus 로고    scopus 로고
    • Clinical trials in multiple sclerosis. Chap 20
    • Cutter G., Kappos L. Clinical trials in multiple sclerosis. Chap 20. Handbook of Clinical Neurology 2014, 122(3rd series):445-453.
    • (2014) Handbook of Clinical Neurology , pp. 445-453
    • Cutter, G.1    Kappos, L.2
  • 43
    • 0027530638 scopus 로고
    • Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
    • The Parkinson Study Group Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 1993, 328:176-183.
    • (1993) N. Engl. J. Med. , vol.328 , pp. 176-183
  • 44
    • 33645894705 scopus 로고    scopus 로고
    • A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease
    • NINDS NET-PD Investigators A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2006, 66:664-671.
    • (2006) Neurology , vol.66 , pp. 664-671
  • 45
    • 84924034345 scopus 로고    scopus 로고
    • Problems with constructing tests to accept the null hypothesis
    • Chap 4 in. Interdisciplinary Bayesian Statistics
    • Rogatko A., Piantadosi S. Problems with constructing tests to accept the null hypothesis. Springer Proc in Math & Stat 2015, 118:49-54.
    • (2015) Springer Proc in Math & Stat , vol.118 , pp. 49-54
    • Rogatko, A.1    Piantadosi, S.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.